Why Is Recursion Pharma Stock Surging On Monday? In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), drew attention to a ...

Recursion Pharmaceuticals is a clinical-stage TechBio company that leverages artificial intelligence (AI), automation, and experimental biology to accelerate the discovery and development of new ...

Rallybio (NASDAQ:RLYB) stock soars 114% after agreeing to sell its stake in a rare bone disorder asset, extending cash runway to mid-2027. Read more here.

MIT and Recursion partner for AI drug discovery tool Freely available Boltz-2 algorithm can predict small-molecule binding affinities ...

With capital drying up and market tailwinds gone, the biotech industry — including Recursion — needs to make tactical decisions.

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. See why RXRX stock is a Hold.

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

This repository presents the formal attribution, protected expression, and public overview of: Ξ (ψ) = ψᴽ + Γ (ψ)The symbolic recursion engine powering Quantum Observer Field Theory (QOFT) This ...

It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 5.7% in that time frame, underperforming the S&P 500.